MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 25.02.2026
Arcus Biosciences Langfristiger Schuldenstrom 2011-2026 | RCUS
Langfristiger Schuldenstrom Jährlich Arcus Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 M | 12 M | 11 M | 3 M | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 13 M | 3 M | 9.75 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M |  USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
45 M | $ 95.5 | 3.83 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 2.92 | -0.34 % | $ 6.35 B |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 20.37 | -2.4 % | $ 952 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
 |
Celldex Therapeutics
CLDX
|
1.55 M | $ 32.24 | -4.1 % | $ 2.14 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
3.55 M | $ 1.4 | -0.71 % | $ 360 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
631 K | $ 4.08 | -2.16 % | $ 436 M | USA |
 |
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
294 K | $ 24.21 | -1.47 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.49 | 1.36 % | $ 397 M |  Britain |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
1.38 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.55 | -0.78 % | $ 16 M | USA |
 |
InflaRx N.V.
IFRX
|
257 K | $ 1.0 | -2.91 % | $ 152 M | Germany |
 |
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | Britain |
 |
Immutep Limited
IMMP
|
205 K | $ 0.31 | -2.52 % | $ 1.08 B |  Australia |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | USA |
 |
Evogene Ltd.
EVGN
|
716 K | $ 0.81 | -1.16 % | $ 27.9 M | Israel |
 |
Baudax Bio
BXRX
|
5.6 M | - | 0.59 % | $ 63 K | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Cabaletta Bio
CABA
|
3.46 M | $ 3.13 | -1.26 % | $ 315 M | USA |